clinicaltrials

iBio Provides Updates on COVID-19 Vaccine Program

iBio Provides Updates on COVID-19 Vaccine Program

iBio, Inc. (NYSE: IBIO) announced Thursday that immunization studies for its SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) are proceeding at Texas A&M University System (“TAMUS”) laboratories. Ac..